Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Robohogs who wrote (6230)	4/28/2002 12:16:54 AM
From: Biomaven	Read Replies (3) \| Respond to of 52153

Jon, This information isn't exactly new - patent expirations are about the most predictable items in all of biotech and pharma. <g> (Of course they are not totally predictable - just ask the generics manufacturers about the delaying tactics.) Incidentally this table somehow manages to omit the biggest expiration of all - Prilosec. I have some hope that the patent expirations will take some pressure off the drug cost containment issue and leave space for some new drugs. Is the ICN Intron patent really up in 2002? Peter P.S. You can make it look pretty either by selecting "fixed font" in the post or by using a "PRE" tag just like you do with italics or bold. Peter